Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer

Bladder Cancer

Volumn 1, Issue 1, 2015, Pages 65-72

  Steinberg, Ryan L ^a   Thomas, Lewis J ^a   O’Donnell, Michael A ^a   Nepple, Kenneth G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Bladder; Docetaxel; Gemcitabine; Instillation; Salvage therapy; Urinary bladder neoplasms

Indexed keywords

EID: 84947250665     PISSN: 23523727     EISSN: 23523735     Source Type: Journal    
DOI: 10.3233/BLC-150008     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians 2014;64(1):9-29.
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. European Urology 2013;64(4):639-53.
3. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. The Journal of Urology 2003;169(1):90-5.
4. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. The Journal of Urology 2000;163(4):1124-9.
5. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumor progression. Urology 2004;63(4):682-6; discussion 6-7.
6. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. The Journal of Urology 2002;168(5):1964-70.
7. Nepple KG, Lightfoot AJ, Rosevear HM, O’Donnell MA, Lamm DL, Bladder Cancer Genitourinary Oncology Study G. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. The Journal of Urology 2010;184(5):1915-9.
8. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. The Journal of Urology 2007;178(6):2314-30.
9. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: A prospective randomized study. The Journal of Urology 2003;170(3):777-82.
10. Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004;63(3):466-71.
11. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. The Journal of Urology 1987;137(2):220-4.
12. Holzbeierlein JM, Waldsachs Isett W. Supply and demand: Dealing with drug shortages. Global Connections 2013:4-8.
13. American Urological Association. Policy Blog: Important Updates on BCG Availability 2014 [cited 2014 September 9th]. Available from: http://www.auanet.org/advocacy/policy-blog.cfm.
14. Lightfoot AJ, Breyer BN, Rosevear HM, Erickson BA, Konety BR, O’Donnell MA. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. Urologic Oncology 2014;32(1):35 e15-9.
15. O’Donnell MA, Boehle A. Treatment options for BCG failures. World J Urol 2006;24(5):481-7.
16. Eli Lilly and Company. Gemzar (gemcitabine for injection, USP) [Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2014 [cited 2014 September 18, 2014]. Available from: http://www.gemzar.com.
17. Sanofi-Aventis U.S. LLC. Taxotere [Package Insert]. Bridge-water, NJ: Sanofi-Aventis U.S. LLC; 2013 [cited 2014 September 18, 2014]. Available from: http://products.sanofi.us/Taxotere/taxotere.html.
18. Lightfoot AJ, Rosevear HM, Nepple KG, O’Donnell MA. Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade nonmuscle invasive bladder cancer. International Journal of Urology: Official Journal of the Japanese Urological Association 2012;19(11):988-93.
19. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2001;19(3):666-75.
20. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. The Journal of Urology. 2000;164(3 Pt 1):680-4.
21. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? The Journal of Urology 2001;166(4):1296-9.
22. Joudi FN, Smith BJ, O’Donnell MA, National BCGIPIG. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urologic Oncology 2006;24(4):344-8.
23. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. The Journal of Urology 1999;161(4):1124-7.
24. Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urologic Oncology 2013;31(8):1635-42.
25. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. The Journal of Urology 2000;163(3):761-7.
26. McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2006;24(19):3075-80.
27. Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy. The Journal of Urology 2013;189(3):834-9.
28. Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz HJ, Lee CT, et al. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin. The Journal of Urology 2013;190(4):1200-4.
29. Oosterlinck W, Kirkali Z, Sylvester R, da Silva FC, Busch C, Algaba F, et al. Sequential intravesical chemoimmunother-apy with mitomycin C and bacillus Calmette-Guerin and with bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: Results of an EORTC genitourinary group randomized phase 2 trial (30993). European Urology 2011;59(3):438-46.
30. Breyer BN, Whitson JM, Carroll PR, Konety BR. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urologic Oncology 2010;28(5):510-4.